Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy (Q33584240)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

anti-retroviral agent

0 references

object named as

Szu-Min Hsieh

3

0 references

Wang-Huei Sheng

object named as

Wang-Huei Sheng

4

0 references

object named as

Hsin-Yun Sun

5

0 references

Chien-Ching Hung

object named as

Chien-Ching Hung

8

0 references

author name string

Chien-Yu Cheng

1

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Mao-Yuan Chen

2

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Yi-Chun Lo

6

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Wen-Chun Liu

7

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

publication date

21 May 2010

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

BMC Infectious Diseases

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

126

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Role of co-trimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Mycobacterium avium complex in patients with HIV infection in the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Pneumocystis pneumonia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Discontinuation of secondary prophylaxis for Pneumocystis carinii pneumonia in human immunodeficiency virus-infected patients: a randomized trial by the CIOP Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Cotrimoxazole prophylaxis in adults infected with HIV in low-income countries.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Pulmonary manifestations of HIV infection in the era of highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

21 June 2018

A prospective multicentre study of discontinuing prophylaxis for opportunistic infections after effective antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Discontinuation of primary prophylaxis for Pneumocystis carinii pneumonia and toxoplasmic encephalitis in human immunodeficiency virus type I-infected patients: the changes in opportunistic prophylaxis study.

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Discontinuation of Pneumocystis carinii prophylaxis in patients infected with human immunodeficiency virus: a meta-analysis and decision analysis

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Clinical spectrum, morbidity, and mortality of acquired immunodeficiency syndrome in Taiwan: a 5-year prospective study

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Long-term safety of discontinuation of secondary prophylaxis against Pneumocystis pneumonia: prospective multicentre study

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Incidence of neutropenia in HIV-infected African adults receiving co-trimoxazole prophylaxis: a 6-year cohort study in Abidjan, Côte d'Ivoire

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Safe discontinuation of primary pneumocystis prophylaxis in Southern Indian HIV-infected patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Discontinuation of primary prophylaxis in HIV-infected patients at high risk of Pneumocystis carinii pneumonia: prospective multicentre study

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Improved survival of persons with human immunodeficiency virus type 1 infection in the era of highly active antiretroviral therapy in Taiwan

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Severe cutaneous reactions to sulfadoxine-pyrimethamine and trimethoprim-sulfamethoxazole in Blantyre District, Malawi

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

A community-based study of the incidence of trimethoprim-sulfamethoxazole-preventable infections in Malawian adults living with HIV.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Can chemoprophylaxis against opportunistic infections be discontinued after an increase in CD4 cells induced by highly active antiretroviral therapy?

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

A prospective study of discontinuing primary and secondary Pneumocystis carinii pneumonia prophylaxis after CD4 cell count increase to > 200 × 106/l

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

A Randomized Trial of the Discontinuation of Primary and Secondary Prophylaxis againstPneumocystis cariniiPneumonia after Highly Active Antiretroviral Therapy in Patients with HIV Infection

1 reference

https://api.crossref.org/works/10.1186/1471-2334-10-126

21 January 2018

Balancing individual benefit against public health risk: the impact of cotrimoxazole prophylaxis in HIV-infected patients on antimicrobial resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2885390

31 October 2018

Discontinuation of chemoprophylaxis against Pneumocystis carinii pneumonia in patients with HIV infection. HIV Outpatient Study (HOPS) Investigators

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4 T lymphocyte counts above prophylaxis thresholds

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Epidemiology of Pneumocystis carinii pneumonia in an era of effective prophylaxis: the relative contribution of non-adherence and drug failure

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pneumocystis carinii Pneumonia Recurrence in HIV Patients on Highly Active Antiretroviral Therapy: Secondary Prophylaxis

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Cotrimoxazole prophylaxis in HIV-infected individuals after completing anti-tuberculosis treatment in Thyolo, Malawi

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4 T-cell count < 200 cells/??l when viral replication is suppressed

1 reference

https://pubmed.ncbi.nlm.nih.gov/20492660

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1471-2334-10-126

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

28 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33584240&oldid=2195523248"